竣球控股(01481.HK)擬3000萬港元認購湖北康時珍醫藥30%經擴大註冊資本
格隆匯7月15日丨竣球控股(01481.HK)發佈公吿,2022年7月15日,公司與目標公司訂立協議,據此,認購人(即公司)有條件同意認購完成後目標公司(即湖北康時珍醫藥科技有限公司)經擴大註冊資本的30%,認購價為3000萬港元。於該公吿日期,目標公司由嚴福全持有65%及由福佑醫藥科技(蘇州)有限公司持有35%。
根據披露,目標公司主要從事醫藥研究、藥物開發、製造及銷售,其主要專注於生產及銷售原料藥天然“紫杉醇(Paclitaxel) 原料藥”、半合成前列腺癌抗癌藥“卡巴他賽(Cabazitaxel)原料藥”及副產品“10- 去乙酰基巴卡汀 III”。目標公司目前正在評估紫杉醇注射液及卡巴他賽注射液的仿製藥的一致性。取決於新藥一致性評估,目標公司擬於2023年底前在全球市場將新藥投入市場及商業化。
紫杉醇為一種重要的抗腫瘤藥物,該等腫瘤包括卵巢癌、乳腺癌和非小細胞肺癌。根據市場研究及諮詢機構Precedence Research,2021年全球紫杉醇注射液市場規模約為45.1億美元,預計於2030年將達到約111.6億美元,年複合增長率約為10.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.